Q-omics provides the consensus-scored FAM227B profile across patient tissues and cancer cell-line models. FAM227B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM227B is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, FAM227B RNA expression shows 21,129 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where FAM227B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM227B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM227B survival associations across molecular data types. FAM227B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM227B RNA expression–survival associations across cancer types. High FAM227B expression shows favorable associations in KIRC, UCS, UVM, LIHC, MESO and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM227B RNA expression.
This table summarizes FAM227B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for FAM227B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM227B shows lower tumor expression in THCA, KIRC, KICH, KIRP, UCEC and LUAD. The THCA box plot shows higher FAM227B RNA expression in normal versus tumor tissue (log2 FC = −0.772, t-test p < 0.001).
This table shows molecular features associated with FAM227B in patient tissues and cancer cell lines. In patient samples, FAM227B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM227B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
